Califf Gets Unanimous Committee Vote Supporting FDA Commissioner Bid
This article was originally published in Clinica
Executive Summary
After being thoroughly questioned, Robert Califf won a unanimous vote in support of his bid to become the next FDA commissioner from the Senate Health, Education, Labor and Pensions Committee on Jan. 12. Califf, who currently serves as FDA's deputy commissioner for medical products and tobacco, still requires full Senate approval and is likely to find some challenges there.
You may also be interested in...
Califf Clears First Senate Hurdle, But Could FDA’s Abortion Pill Access Decision Be A Headache?
Robert Califf’s nomination to be the next US FDA commissioner squeaked out of the Senate health committee, but a significant number of Republicans are against his confirmation over the agency’s recent decisions on abortion drugs.
Life After NASH For CymaBay: An Interview With CEO Sujal Shah
With up to $100m from Abingworth and a recent $75m FOPO, CymaBay has runway to await pivotal data in primary biliary cholangitis in 2023 for seladelpar, after the candidate failed in NASH. It sees a significant market opportunity in the second-line setting cornered by Intercept.
FDA, Industry To Miss MDUFA V Congressional Deadline; Insiders At Odds Over Future Of Deal
The US agency and the medtech industry still have significant disagreements, which means they will miss a 15 January deadline to send the MDUFA V user-fee deal to Congress. Insiders disagree, however, on how severe those disagreements are and when a deal can be reached.